Trastuzumab (procedure code 1-J9355) is a benefit of the CSHCN Services Program as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant treatment of clients with HER2 overexpressing, node positive breast cancer. Trastuzumab is a benefit for the following diagnosis codes:
Diagnosis Code
Description
1740
Malignant neoplasm of nipple and areola of female breast
1741
Malignant neoplasm of central portion of female breast
1742
Malignant neoplasm of upper-inner quadrant of female breast
1743
Malignant neoplasm of lower-inner quadrant of female breast
1744
Malignant neoplasm of upper-outer quadrant of female breast
1745
Malignant neoplasm of lower-outer quadrant of female breast
1746
Malignant neoplasm of axillary tail of female breast
1748
Malignant neoplasm of other specified sites of female breast
1749
Malignant neoplasm of breast (female), unspecified site
1750
Malignant neoplasm of nipple and areola of male breast
1759
Malignant neoplasm of other and unspecified sites of male breast
Texas Medicaid & Healthcare Partnership CPT only copyright 2007 American Medical Association. All rights reserved.
